Lexaria Bioscience (LEXX) Share-based Compensation Growth (1y) (2018 - 2026)
Lexaria Bioscience (LEXX) Share-based Compensation Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -7.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -8.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -22.43% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 11.71% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -4.01% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -81.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -81.36% |
| Feb 28, 2026 | -55.21% |
| Nov 30, 2025 | -24.66% |
| Aug 31, 2025 | 27.16% |
| May 31, 2025 | 45.90% |
| Nov 30, 2024 | 84.26% |
| Aug 31, 2024 | 901.76% |
| May 31, 2024 | 319.63% |
| Nov 30, 2023 | -21.55% |
| Aug 31, 2023 | -95.86% |
| May 31, 2023 | -26.74% |
| Nov 30, 2022 | -83.17% |
| May 31, 2022 | -72.88% |
| Nov 30, 2021 | 10,580.89% |
| May 31, 2021 | -39.93% |
| Feb 28, 2021 | -101.30% |
| Nov 30, 2020 | -97.64% |
| Aug 31, 2020 | -1,104.13% |
| May 31, 2020 | 81.38% |
| Feb 29, 2020 | 124.65% |